Apyx Medical Corp

Apyx Medical Corporation announced its 2026 Annual Meeting of Stockholders will be held on August 6, 2026, at 9:00 a.m. EST in Uniondale, New York. Stockholders will vote on the election of five directors, the ratification of RSM US LLP as the independent auditor, a non-binding advisory resolution on executive compensation, and the approval of the 2026 Share Incentive Plan. The record date for determining stockholders entitled to vote is June 15, 2026. The Board unanimously recommends voting in favor of all proposals.

Apyx Medical Corporation announced the publication of new clinical data in Aesthetic Surgery Journal Open Forum. The study highlights a promising approach to improving cellulite and skin laxity using a combination treatment of Avéli for targeted subcision and Renuvion for skin laxity. Results at 180 days post-treatment showed up to 81.8% of patients improved in cellulite appearance, with objective 3D imaging demonstrating measurable reductions in dimple volume, surface area, and depth. Histological analysis also showed increases in collagen and elastin, indicating progressive tissue remodeling.

Apyx Medical announced the publication of new clinical data in Aesthetic Surgery Journal Open Forum, highlighting a promising approach to improving cellulite and skin laxity. The prospective investigator-initiated clinical study evaluated a combination treatment utilizing Avéli® for targeted subcision and Apyx's Renuvion® to reduce skin laxity. Results showed progressive improvement over time, with up to 81.8% of patients demonstrating improved cellulite appearance and increased levels of collagen and elastin observed in a subset through 180 days post-treatment.

Apyx Medical Corporation announced the publication of a new retrospective investigator-initiated study in Plastic and Reconstructive Surgery - Global Open. The study evaluated patient-reported outcomes following liposuction with and without helium plasma radiofrequency (Renuvion®). Results showed statistically significant improvements in patient satisfaction with abdominal appearance and excess skin, along with lower rates of abdominoplasty and surgical revisions, while maintaining comparable complication rates.

Apyx Medical Corporation announced it received expanded 510(k) clearance from the U.S. Food and Drug Administration for its AYON Body Contouring System. This clearance now includes power liposuction, an advanced modality designed to enhance the efficiency of fat removal and reduce surgeon effort. The company anticipates this addition will significantly increase market demand for the AYON system and plans a limited commercial launch to refine training and customer experience.

Apyx Medical Corporation announced it received expanded 510(k) clearance from the U.S. FDA for its AYON Body Contouring System to include power liposuction. This advanced function uses a reciprocating cannula to improve fat removal efficiency, reducing surgeon effort and operating room time. The company plans a limited commercial launch of the power liposuction function, aiming to refine training and customer experience before broader adoption, and believes this integration makes AYON the gold-standard in surgical aesthetics.

Apyx Medical Corp reported a significant improvement in its first-quarter 2026 financial results, with net sales increasing by 32% to $12.49 million and net loss attributable to stockholders nearly halving to $2.11 million from $4.15 million in the prior year. The company also submitted a 510(k) premarket notification to the FDA for label expansion of its AYON Body Contouring System to include power liposuction, with clearance anticipated in Q2 2026. Apyx believes the increasing use of GLP-1 drugs, while initially impacting revenue, could eventually drive demand for its Renuvion products due to associated loose skin.

Apyx Medical Corporation reported strong first-quarter 2026 financial results, with total revenue increasing 32.4% to $12.5 million, primarily driven by a 36.1% growth in its Surgical Aesthetics segment. The company significantly reduced its net loss to $2.1 million and its Adjusted EBITDA loss to $0.3 million compared to the prior year. Following this performance, Apyx Medical raised its full-year 2026 total revenue guidance to a range of $59.0 million to $60.0 million.

Apyx Medical Corporation announced it will release its first-quarter fiscal year 2026 financial results before markets open on Thursday, May 7th. Management will host a conference call at 8:00 a.m. Eastern Time on the same day to discuss the results, followed by a question-and-answer session. Interested parties can join the call by phone or via a live webcast.